MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why AARD Stock dropped -4.64% Today — RQD Quant Desk Flash
$1.44 -4.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.43
Aardvark Therapeutics Inc. (AARD) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $31.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.43 (-1.03%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AARD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY AARD SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 24.9 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$4.76-20.6% Next Q
45
Q2 (-2Q)Grade D$3.78-63.2% Next Q
42
Q3 (-1Q)Grade D$1.39+3.6% Next Q
40
CurrentGrade D-$1.44-8.1% Hist 90D α
37
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AARD Turnaround Squeeze
While AARD currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.77) and Max Pain ($1.51) forces dealer call-delta covering toward $17.43.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AARD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AARD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AARD Stock dropped -4.64% Today — RQD Quant Desk Flash
Aardvark Therapeutics Inc. (AARD) dropped -4.64% to $1.44, trading at 3% of its 52-week range ($0.93 – $16.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.93 – $16.6) with RSI-14 at 24.9 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live AARD Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AARD)
- ✓Walkthrough of AARD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AARD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.48%🛡️ HOLDING TREND SUPPORT
2026-10-30O $1.39H $1.46L $1.33C $1.44VOL 463.8K
RES: $10.18SUP: $0.82SMA50: $4.77SMA200: $6.32
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AARD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AARD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AARD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AARD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AARD)
Health Care Rank #761 of 1016
⚔️ FLNA vs AARD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AARD vs. FLNA, IXHL, IBO, NXTC)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aardvark Therapeutics Inc. (AARD) ranks #761 by composite RQD confidence (37/100, grade D-) and #799 by equity capitalization ($31.5M). Within this direct 5-issuer industry benchmark cohort, AARD leads on earnings valuation at N/A trailing P/E, while IBO leads on capital efficiency and profitability with -27.5% ROIC and -30.0% gross margin. NXTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with AARD at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AARD
ACTIVE
Aardvark Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -4.64% | $31.5M | Benchmark Subject |
| FLNA Filana Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +1.12% | $31.8M | /flna-vs-aard → |
| IXHL Incannex Healthcare Inc. | D- | 39/100 | — | — | -35.0% | -4.80% | $32.4M | /ixhl-vs-aard → |
| IBO Impact BioMedical Inc. | E | 34/100 | — | -30.0% | -27.5% | -3.00% | $33.1M | /ibo-vs-aard → |
| NXTC NextCure Inc. | D | 48/100 | — | — | -35.0% | +2.92% | $29.9M | /nxtc-vs-aard → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001774857In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aardvark Therapeutics Inc. (AARD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$57.6M, operating cash flow of -$54.2M, and free cash flow of -$54.3M (-198.2% YoY). On the balance sheet, AARD closed FY2025 with $117.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$57.6M | -$54.2M | -$54.3M | $117.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$20.6M | -$18.1M | -$18.2M | $77.5M | — |
3. AARD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AARD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Aardvark Therapeutics Inc. (NASDAQ: AARD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.44 (-4.64% 1D, market cap $31.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AARD ranks #761 in composite RQD confidence.
How does AARD compare to FLNA and IXHL in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AARD carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FLNA (Filana Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $31.8M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, AARD leads on earnings multiple (N/A) while IBO leads on capital efficiency (-27.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AARD?
Per AARD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001774857), Aardvark Therapeutics Inc. generated $0 in revenue, -$57.6M in net income, and -$54.3M in free cash flow against $117.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AARD trading relative to its 50-day, 200-day, and 52-week technical levels?
AARD last traded at $1.44 (-4.64% on volume of 955,921 shares), positioning the stock -69.81% below its 50-day simple moving average ($4.77) and -77.22% below its 200-day simple moving average ($6.32). Across its 52-week range of $0.93 to $16.60, AARD sits at the 3.3% percentile with a 14-day RSI of 24.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.26 to $1.62).
AARD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AARD stock moving today?
Why AARD Stock dropped -4.64% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.